Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)

NCT00255346 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

68

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia
Myelodysplastic Syndromes
Agnogenic Myeloid Metaplasia
Myelofibrosis
Hypereosinophilic Syndrome
Polycythemia Vera
Mastocytosis
Leukemia, Myelomonocytic, Chronic

Interventions

DRUG: Dasatinib (BMS-354825)

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]